Abstract

BackgroundPatients with opioid use disorder (OUD) frequently present with comorbid psychiatric illnesses which have significant implications for their treatment outcomes. Notably, these are often identified by self-report. Our study examined the sensitivity and specificity of self-reported psychiatric diagnoses against a structured diagnostic interview in a cohort of patients receiving outpatient pharmacological treatment for OUD.MethodsUsing cross-sectional data from adults receiving outpatient opioid agonist treatment for OUD in clinics across Ontario, Canada, we compared participants’ self-reported psychiatric diagnoses with those identified by the Mini Neuropsychiatric Interview (MINI) Version 6.0 administered at the time of study entry. Sensitivity and specificity were calculated for self-report of psychiatric diagnoses.ResultsAmongst a sample of 683 participants, 24% (n = 162) reported having a comorbid psychiatric disorder. Only 104 of these 162 individuals (64%) reporting a comorbidity met criteria for a psychiatric disorder as per the MINI; meanwhile, 304 (75%) participants who self-reported no psychiatric comorbidity were in fact identified to meet MINI criteria for a psychiatric disorder. The sensitivity and specificity for any self-reported psychiatric diagnoses were 25.5% (95% CI 21.3, 30.0) and 78.9% (95% CI 73.6, 83.6), respectively.ConclusionsOur findings raise questions about the utility of self-reported psychiatric comorbidity in patients with OUD, particularly in the context of low sensitivity of self-reported diagnoses. Several factors may contribute to this including remittance and relapse of some psychiatric illnesses, underdiagnosis, and the challenge of differentiating psychiatric and substance-induced disorders. These findings highlight that other methods should be considered in order to identify comorbid psychiatric disorders in patients with OUD.

Highlights

  • Patients with opioid use disorder (OUD) frequently present with comorbid psychiatric illnesses which have significant implications for their treatment outcomes

  • In studying the impact of psychological symptoms in OUD treatment outcomes, we have previously found that psychological symptoms were associated with higher percentages of opioid-positive drug screens (B = 0.02, 95% CI 0.01–0.02 = 3) and non-opioidpositive drug screens (B = 1.92, 95% CI 0.89, 2.95) [14]

  • Data were collected in the GENetics of Opioid Addiction (GENOA) prospective cohort study conducted in Ontario, Canada

Read more

Summary

Introduction

Patients with opioid use disorder (OUD) frequently present with comorbid psychiatric illnesses which have significant implications for their treatment outcomes. The opioid crisis continues to be a major public health problem worldwide [1,2,3,4]. In Canada, overdose deaths and hospitalizations related to opioid use disorder (OUD) have remained high despite increasing awareness and intervention [5, 6]. The impacts of the COVID-19 pandemic have exacerbated preexisting issues relating to access to appropriate treatment and interventions, ensuring that the opioid crisis will remain an ongoing concern for patients and families, healthcare workers, and policymakers alike [9]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call